Sunwin Sells Vet Ops to Focus on Stevia

Qufu, CHINABanking on the sweet future of stevia, Sunwin International Neutraceuticals Inc., announced plans to sell its entire interest in Shengya Veterinary Medicine Co. Ltd. to Laiwang Zhang, the company's president and chairman of its board of directors. The move enables Sunwin to focus efforts on its core business of producing and selling stevia and other herb-based products in China and North America.

The board of directors approved the stock sale and purchase agreement in exchange for 5 million shares of Sunwin common stock owned by Zhang. The deal is expected to close by July 31, 2010.

"We believe the divestiture of this subsidiary will enable our team to focus more of its efforts on our core stevia operations in China and North America, said Dongdong Lin, CEO of Sunwin. We are confident that there is a great future ahead for Sunwin both in stevia and herbal-based products and we intend to utilize all of our resources to make that great future a reality for Sunwin and its shareholders.

Sunwin is one of the top global providers of high-quality stevia extracts, including Rebaudioside A 98. Shengya manufactures and sells a variety of veterinary medicines in China that represented a small percentage of total revenue.